Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase Ib/IIa study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cartesian Therapeutics
• Treatments: Antibodies; Autoantibodies

Criteria

Inclusion Criteria:

• Patient must be at least 18 years of age.

• Patient must have Generalized Myasthenia Gravis at the time of screening.

• Concomitant immunosuppressive drugs must be deemed necessary by the investigator.

Exclusion Criteria:

• Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient.

• Patient is pregnant or lactating.